Interestingly, the expression levels of PRMT1, PRMT2, PRMT4, and PRMT6 in low-grade gliomas are significantly higher in IDH1/2 wild-type (WT) subgroups than the subgroups with the IDH1/2 mutations. Here, IDH1 is linked to central nervous system cancer.